Skip Ribbon Commands
Skip to main content

Adj Prof Huynh The Hung

Adj Prof Huynh The Hung

​• Post-Doc. (Canada) 1994
• Ph.D (Canada) 1993
• M.Sc. (Canada) 1990
• B.Sc. (Canada) 1988

National Cancer Centre Singapore


​Prof Huynh is an adjunct professor at National University Singapore (Singapore) and McGill University (Canada) and also Principal Investigator of Laboratory of Molecular Endocrinology at National Cancer Centre Singapore. He receives several awards including Dean's First Honour List for his Ph.D, The United States Army Medical Research and Materiel Command Breast Cancer Research Program, Best Researcher Award, and Best Paper Award at the 4th Asian Congress in Urology. Prof. Huynh has published as the first or corresponding author in more than 120 peer-reviewed journals.

His research interest is to establish and develop the xenograft models of human solid malignancies in Hepatocellular carcinoma, Gastrointestinal Stromal Tumours, Gastric Cancer, Lung Cancer, Pancreatic Cancer, Breast Cancer, Ovarian Cancer, NPC and Head and Neck cancers from patient’s tumor specimens.  He has developed more than 280 xenograft tumor models including hepatocellular carcinoma (HCC), gastric cancer, gastrointestinal stromal tumors, lung and ovarian cancer. 

Prof. Huynh established National Xenograft Therapeutic Program (NXTP) in 2006. Through this translational platform, he has collaborated with world-famous pharmaceutical companies and institutions including Novartis, AstraZeneca, Roche and Bayer HealthCare with the aim to identify novel treatments for various cancers including hepatocellular carcinoma and gastric cancer.


​• Post-Doc. (Canada) 1994
• Ph.D (Canada) 1993
• M.Sc. (Canada) 1990
• B.Sc. (Canada) 1988

Professional Appointments and Committee Memberships

​· Principal Investigator, Division of Cellular & Molecular Research, National Cancer Centre Singapore 1999 - Present

Academic Appointments

Adjunct Professor
Department of Medicine
National University of Singapore

Adjunct Professor
Department of Medicine
McGill University, Canada


​• American Association for Cancer Research, 2003
• Best Researcher Award, National Cancer Centre Academic Awards, 2001
• Best Grant Award, National Cancer Centre Academic Awards, 2001
• American Association for Cancer Research, 2003
• Best Researcher Award, National Cancer Centre Academic Awards, 2001
• Best Grant Award, National Cancer Centre Academic Awards, 2001
• The United States Army Medical Research and Materiel Command Breast Cancer Research Program Award, 1997-2000
• Fonds de la Recherche en Sante du Quebec Chercheur-boursier Award, 1997-2000
• The 4th Asian Congress in Urology Best Paper Award, 1998
• International Biology of Prostate Growth Symposium Award, 1998
• Canadian Breast Cancer Foundation Award, 1995
• Dean's First Honour List (Ph.D. Degree), 1994
• Natural Scientific and Engineering Research Council Award (NSERC). 1991-1992
• NSERC, 1988-1991
• McConnell, 1986-1988
• Eliza M. Jones, 1986-1988

Research Interests

​• Development of patient-derived solid tumor xenografts for pre-clinical studies of human solid tumors.
• Drug Discovery


1. Hung Huynh, Aldo Prawira, Thi Bich Uyen Le, Thanh Chung Vu, Huai-Xiang Hao, Alan Huang, Youzhen Wang, Diana Graus Porta. FGF401 and vinorelbine synergistically mediates antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma. Experimental and Molecular Medicine. 2020 Nov 52(11): 1857-68   [PMID: 33235319]
2. Thi Bich Uyen Le, Thanh Chung Vu, Rebecca Zhi Wen Ho, Aldo Prawira, Lingzhi Wang, Boon Cher Goh and Hung Huynh.  Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma. International Journal of Molecular Sciences. 2020 Dec 21(24): 9405   [PMID: 33321903]
3. Aldo Prawira, Thi Bich Uyen Le, Thanh Chung Vu, Hung Huynh. Ribociclib enhances Infigratinib-induced cancer cell differentiation and delays resistance in FGFR-driven hepatocellular carcinoma. Liver International 2020 Nov 00:1-13  [PMID: 33179425]
4. Tran A, Koh TS, Prawira A, Ho RZW, Le TBU, Vu TC, Hartano S, Teo XQ, Chen WC, Lee P, Thng CH, Huynh H. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High-FGFR-Expressing Hepatocellular Carcinoma Xenografts. Mol Imaging Biol. 2021 Feb 23(1):70-83 [PMID: 32909245]
5. Kheng Wei Yeoh, Aldo Prawira, Muhammad Zafrie Bin Saad, Kok Ming Lee, Eric Ming Hon Lee, Gee Keng Low, Mohamed Hakim Bin Mohd Nasir, Jun Hao Phua, Wendy Wan Li Chow, Iris Jiu Hia Lim, Yusnita Binte Omar, Rebecca Zhi Wen Ho, Thi Bich Uyen Le, Thanh Chung Vu, Khee Chee Soo and Hung Huynh. Vinorelbine augments radiotherapy in hepatocellular carcinoma. Cancers 2020 Apr 12(4):872 [PMID: 32260169]
6. Li Ren Kong, Nur Afiqah Mohamed Salleh, Richard Weijie Ong, Tuan Zea Tan, Nicholas Syn, Robby Miguel Goh, Chee Wai Fhu, Daniel S.W. Tan, N. Gopalakrishna Iyer, Chandra Verma, Srinivasaraghavan Kannan, Yaw Chyn Lim, Ross Soo, Jingshan Ho, Yiqing Huang, Joline S.J. Lim, Benedict Yan, Min En Nga, Seng Gee Lim, H. Phillip Koeffler, Soo Chin Lee, Dennis Kappei, Huynh Hung, and Boon Cher Goh. A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma. Nature Communication 2020 Mar 11(1): 1556 [PMID: 32214092]
7. Li Ren Kong, Richard Weijie Ong, Tuan Zea Tan, Nur Afiqah Mohamed Salleh, Matan Thangavelu, Jane Vin Chan, Judice Koh, Giridharan Periyasamy, Amelia Lau, Thi Bich Uyen Le, Lingzhi Wang, MiYoung Lee, Srinivasaraghavan Kannan, Chandra Verma, Chwee Ming Lim, CHNG WEE JOO, David Lane, Ashok Venkitaraman, Huynh Hung, Chit Fang Cheok, and Boon Cher Goh. Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation. Nature Communication. 2020 Apr 11(1): 2086  [PMID: 32350249]
8. Henyu Lu, Chen Liu, Hung Huynh, Thi Bich Uyen Le, Matthew J. LaMarche, Morvarid Mohseni, Jeffery A. Engelman, Peter S. Hammerman, Giordano Caponigro and Huai-Xiang Hao. Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR.  Oncotarget, 2020 Jan 11(3): 265-81. [PMID: 32072487]
9. Hung Huynh, Lee Liek Yeow, Goh KY, Richard Ong, Huai-Xiang Hao, Alan Huang, Youzhen Wang, Diana Graus Porta4, Pierce Chow, Alexander Chung. Infigratinib mediates growth inhibition and vascular normalization, impairs metastasis and improves chemotherapy in hepatocellular carcinoma. Hepatology. 2019 March; 69(3):943-958  [PMID: 30575985]
10. Huynh H, Ong R, Goh KY, Lee LY, Puehler F, Scholz A, Politz O, Mumberg D, Ziegelbauer K. Sorafenib/MEK inhibitor combination inhibits tumor growth and the Wnt/β catenin pathway in xenograft models of hepatocellular carcinoma. Int J Oncol. 2019 Mar;54(3):1123-1133 [PMID: 30747223]
11. Kumar R, Coronel L, Somalanka B, Raju A, Aning OA, An O, Ho YS, Chen S, Mak SY, Hor PY, Yang H, Lakshmanan M, Itoh H, Tan SY, Lim YK, Wong APC, Chew SH, Huynh TH, Goh BC, Lim CY, Tergaonkar V, Cheok CF. Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers. Nature Communication. 2018 Sept 26; 9(1):3931. [PMID: 30258081]
12. Fong ELS, Toh TB, Lin QXX, Liu Z, Hooi L, Mohd Abdul Rashid MB, Benoukraf T, Chow EK, Huynh TH, Yu H. Generation of matched patient-derived xenograft in vitro-in vivo models using 3D macroporous hydrogels for the study of liver cancer. Biomaterials. 2018 Mar;159:229-240. [PMID: 29353739]

Research Trials

  • Updated on